In 2015, the Japanese Society for Neuroendocrine Tumors (JNETS) published the first clinical practice guidelines for pancreatic and gastrointestinal neuroendocrine neoplasms (NEN) to standardize diagnosis and treatment. NEN is a rare tumor that develops in all organs and presents with various clinical symptoms. Pathological classification is ultimately important for the diagnosis of NEN, and it is necessary to select drug treatment strategies based on the pathological diagnosis. The second edition of revised guidelines was published in 2019 to reflect new trends, including WHO classification revision, the advent of somatostatin receptor scintigraphy, the addition of target diseases for molecularly targeted drugs and the somatostatin analogue lanreotide, and reexamination of surgical indications for non-functional pancreatic NEN. Peptide receptor radionuclide therapy (PRRT) has also emerged. In this article, we review the current status and future prospects of pancreatic NEN management.
"},{"@language":"ja","@value":"神経内分泌腫瘍（neuroendocrine neoplasm：NEN）の診断および治療の標準化を目指して，日本神経内分泌腫瘍研究会（JNETS）より2015年に初めて膵・消化管NEN診療ガイドラインが発刊された．その後，WHO分類の改訂，ソマトスタチン受容体シンチグラフィーの登場，分子標的薬やストレプトゾシンおよびソマトスタチンアナログのランレオチドが対象疾患の追加，非機能性膵NENに対する手術適応の再検討など，多くのNENに関する新たな動向があり，2019年に第2版が改訂され発刊された．その後，ペプチド受容体放射性核種療法（PRRT）も登場してきた．NENは希少腫瘍であるとともに，全身臓器に発生して多彩な臨床症状を呈する．NENの診断には最終的に病理分類が重要であり，病理診断に基づいた薬物治療戦略の選択が必要となる．本稿では，膵NEN診療の現状および今後の展望について総説する．
"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410580085008992642","@type":"Researcher","foaf:name":[{"@language":"ja","@value":"伊藤 鉄英"},{"@language":"en","@value":"ITO Tetsuhide"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital"},{"@language":"ja","@value":"福岡山王病院膵臓内科・神経内分泌腫瘍センター"},{"@language":"en","@value":"Department of Gastroenterology, Graduate School of Medical Sciences, Internal University of Health and Welfare"},{"@language":"ja","@value":"国際医療福祉大学医学部消化器内科学"}]},{"@id":"https://cir.nii.ac.jp/crid/1410580085008992640","@type":"Researcher","foaf:name":[{"@language":"ja","@value":"高松 悠"},{"@language":"en","@value":"TAKAMATSU Yu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital"},{"@language":"ja","@value":"福岡山王病院膵臓内科・神経内分泌腫瘍センター"}]},{"@id":"https://cir.nii.ac.jp/crid/1410580085008992641","@type":"Researcher","foaf:name":[{"@language":"en","@value":"UEDA Keijiro"},{"@language":"ja","@value":"植田 圭二郎"}],"jpcoar:affiliationName":[{"@language":"ja","@value":"福岡山王病院膵臓内科・神経内分泌腫瘍センター"},{"@language":"en","@value":"Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital"},{"@language":"en","@value":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences"},{"@language":"ja","@value":"九州大学医学部病態制御内科"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09130071"},{"@type":"LISSN","@value":"09130071"},{"@type":"EISSN","@value":"18812805"}],"prism:publicationName":[{"@language":"en","@value":"Suizo"},{"@language":"ja","@value":"膵臓"},{"@language":"en","@value":"Journal of the Japan Pancreas Society"},{"@language":"en","@value":"Suizo"},{"@language":"en","@value":"J. JPN. PANC. SOC."},{"@language":"ja","@value":"膵臓"}],"dc:publisher":[{"@language":"en","@value":"Japan Pancreas Society"},{"@language":"ja","@value":"一般社団法人 日本膵臓学会"}],"prism:publicationDate":"2023-12-28","prism:volume":"38","prism:number":"6","prism:startingPage":"361","prism:endingPage":"366"},"reviewed":"false","url":[{"@id":"https://www.jstage.jst.go.jp/article/suizo/38/6/38_361/_pdf"}],"availableAt":"2023-12-28","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=%E8%86%B5%E3%83%BB%E6%B6%88%E5%8C%96%E7%AE%A1%E7%A5%9E%E7%B5%8C%E5%86%85%E5%88%86%E6%B3%8C%E8%85%AB%E7%98%8D","dc:title":"膵・消化管神経内分泌腫瘍"},{"@id":"https://cir.nii.ac.jp/all?q=%E8%A8%BA%E7%99%82%E3%82%AC%E3%82%A4%E3%83%89%E3%83%A9%E3%82%A4%E3%83%B3","dc:title":"診療ガイドライン"},{"@id":"https://cir.nii.ac.jp/all?q=%E8%A8%BA%E6%96%AD","dc:title":"診断"},{"@id":"https://cir.nii.ac.jp/all?q=%E6%B2%BB%E7%99%82","dc:title":"治療"},{"@id":"https://cir.nii.ac.jp/all?q=Gastrointestinal-pancreatic%20neuroendocrine%20neoplasm","dc:title":"Gastrointestinal-pancreatic neuroendocrine neoplasm"},{"@id":"https://cir.nii.ac.jp/all?q=Clinical%20practice%20guideline","dc:title":"Clinical practice guideline"},{"@id":"https://cir.nii.ac.jp/all?q=Diagnosis","dc:title":"Diagnosis"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment","dc:title":"Treatment"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231346818432","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236369378304","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rb Loss and\n KRAS\n Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168761839360","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and response after peptide receptor radionuclide therapy with 177Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298341437617792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298764684438912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092802876416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long‐term safety and efficacy of lanreotide autogel in Japanese patients with neuroendocrine tumors: Final results of a phase II open‐label extension study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580230626515328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593692171648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861711783100672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861712127378176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995611481344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419724812160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368876190848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320401234560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001288143884416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Postoperative adjuvant therapy for patients with Pancreatic Neuroendocrine Neoplasms"},{"@language":"ja","@value":"膵神経内分泌腫瘍に対する術後補助療法"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400759673216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2012318613"},{"@type":"CROSSREF","@value":"10.2958/suizo.38.361"}]}